IRIS
COSTANTINI, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.056
EU - Europa 2.024
AS - Asia 1.506
SA - Sud America 457
AF - Africa 79
OC - Oceania 26
Continente sconosciuto - Info sul continente non disponibili 1
Totale 8.149
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.015
SG - Singapore 544
IT - Italia 428
CN - Cina 411
BR - Brasile 381
UA - Ucraina 306
SE - Svezia 251
RU - Federazione Russa 211
DE - Germania 194
HK - Hong Kong 188
IE - Irlanda 181
VN - Vietnam 144
DK - Danimarca 96
GB - Regno Unito 89
FR - Francia 80
FI - Finlandia 72
TR - Turchia 70
KR - Corea 52
NL - Olanda 39
CI - Costa d'Avorio 37
AR - Argentina 32
IN - India 28
AU - Australia 25
AT - Austria 18
MX - Messico 17
BD - Bangladesh 16
CA - Canada 16
EC - Ecuador 13
PL - Polonia 13
CO - Colombia 12
BE - Belgio 11
MA - Marocco 11
EG - Egitto 10
ID - Indonesia 10
ZA - Sudafrica 10
ES - Italia 9
JP - Giappone 9
PY - Paraguay 9
IQ - Iraq 7
AE - Emirati Arabi Uniti 6
RO - Romania 6
VE - Venezuela 6
CH - Svizzera 5
LT - Lituania 5
IL - Israele 4
AL - Albania 3
BG - Bulgaria 3
DO - Repubblica Dominicana 3
NP - Nepal 3
TN - Tunisia 3
UZ - Uzbekistan 3
CL - Cile 2
KE - Kenya 2
KZ - Kazakistan 2
NG - Nigeria 2
TH - Thailandia 2
AM - Armenia 1
AZ - Azerbaigian 1
BB - Barbados 1
BJ - Benin 1
BS - Bahamas 1
CG - Congo 1
DZ - Algeria 1
EU - Europa 1
GA - Gabon 1
GT - Guatemala 1
GY - Guiana 1
HU - Ungheria 1
IS - Islanda 1
JM - Giamaica 1
KG - Kirghizistan 1
LB - Libano 1
LV - Lettonia 1
MN - Mongolia 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PS - Palestinian Territory 1
RS - Serbia 1
UY - Uruguay 1
Totale 8.149
Salva come PNG Salva come JPEG
Città #
Dallas 430
Ashburn 428
Chandler 376
Jacksonville 317
Singapore 314
Fairfield 247
Boardman 186
Hong Kong 186
Dublin 179
Wilmington 144
Des Moines 127
New York 115
Woodbridge 112
Beijing 108
Seattle 97
Ann Arbor 85
Houston 78
Los Angeles 73
San Mateo 73
Lawrence 71
Princeton 71
Rome 61
Redmond 58
Ho Chi Minh City 56
Hefei 53
Cambridge 49
The Dalles 44
San Diego 40
Centro 38
Abidjan 37
Moscow 37
Ancona 33
Chicago 33
Munich 32
São Paulo 30
Buffalo 28
Hanoi 27
Guangzhou 21
Marche 21
London 18
Milan 17
Turin 16
Turku 16
Melbourne 15
Rio de Janeiro 15
Florence 12
Istia D'ombrone 12
Norwalk 12
Phoenix 12
Wuhan 12
Brussels 11
Columbus 11
Helsinki 11
Shanghai 11
Warsaw 11
Washington 11
Charlotte 10
Chennai 10
Brooklyn 9
Civitanova Marche 9
Paris 9
Porto 9
Quanzhou 9
Atlanta 8
Boston 8
Chiaravalle 8
Da Nang 8
Denver 8
Kingscliff 8
Miami 8
Salt Lake City 8
Dhaka 7
Elk Grove Village 7
Genoa 7
Istanbul 7
Johannesburg 7
Nuremberg 7
Vienna 7
Belo Horizonte 6
Buenos Aires 6
Frankfurt am Main 6
Guayaquil 6
Mcallen 6
Montreal 6
Ninh Bình 6
Perugia 6
Poplar 6
Ribeirão Preto 6
Santa Clara 6
Stockholm 6
Wuxi 6
Amsterdam 5
Betim 5
Biên Hòa 5
Bogotá 5
Curitiba 5
Dongguan 5
Guarulhos 5
Kazan' 5
Mexico City 5
Totale 5.039
Salva come PNG Salva come JPEG
Nome #
A novel method to evaluate prethawing viability of cryopreserved CD34+ hematopoietic stem cells for autologous transplantation. 181
Immunomodulatory Effects of Tyrosine Kinase Inhibitor In Vitro and In Vivo Study 153
Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting 145
Age-related M1/M2 phenotype changes in circulating monocytes from healthy/unhealthy individuals 142
Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy 142
Abnormalities of erythropoiesis during HIV-1 disease: a longitudinal analysis. 140
Gut epithelial impairment, microbial translocation and immune system activation in inflammatory bowel disease–associated spondyloarthritis 137
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 133
Higly active antiretroviral therapy induces specific changes in effector and central memory T cell sub-populations 132
A new method to assess the viability of collected CD34+ cells before reinfusion: a prospective study in 50 autotransplanted patients. 132
In vitro comparison of different TKI activity in T-Cell populations: selective sparing of Treg by Nilotinib. 132
Tollerabilità metabolica e durevolezza degli schemi antiretrovirali comprendenti nevirapina (Durability and tolerability of long-term nevirapine-based HAART). 127
Quantification of the HIV-1 total reservoir in the peripheral blood of naïve and treated patients by a standardised method derived from a commercial HIV-1 RNA quantification assay. 124
Cost of HAART in Italy: multicentric evaluation and determinants from a large HIV outpatient cohort. 122
Response to: Letter to the Editor on “Bonafè M, Prattichizzo F, Giuliani A, Storci G, Sabbatinelli J, Olivieri F. Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. Cytokine Growth Factor Rev” by Eugenia Quiros-Roldan, Giorgio Biasiotto and Isabella Zanella 120
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV. 116
Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI. 113
Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy. 111
CROI 2013: le ricadute per la pratica clinica. 111
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 110
Nilotinib Treatment of Patients Affected by Chronic Graft-versus-Host Disease Reduces Collagen Production and Skin Fibrosis by Downmodulating the TGF-β and p-SMAD Pathway 107
Effects of cryopreservation on lymphocyte immunophenotype and function 107
Late or missed HIV diagnosis during pregnancy is still occurring in a high-income country and represents a high risk of MTCT 106
Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. 106
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. 102
OC-34 Clinical outcome of switching to a dual drug regimen (2DR) vs. switching or remaining on a triple (3DR) regimen in the setting of a viral load ≤50 copies/mL 101
Comparsa di polmonite in soggetto con storia recente di inappetenza, disfagia, calo ponderale, ed eritema diffuso. 100
PROGETTO E-PROs: COSTRUZIONE DI UNA PIATTAFORMA DIGITALE PER LA GESTIONE DI STRUMENTI CENTRATI SUL PAZIENTE NELLA PRATICA CLINICA (The E-PROs Project: creation of a digital platform to manage patient-oriented tools in clinical practice). 99
Activated switched memory B cell clusters in chronic spontaneous urticaria are increased in subjects with long disease duration and relapse upon omalizumab discontinuation: Results of the IL-10-OMZ study 98
POOR RESPONSE TO FIRST BNT162B2 SARS-COV-2 VACCINE DOSE IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT 98
Efficacy and costs of Direct Acting Antivirals (DAAS) for the treatment of HCV Iinfection amnog HCV-monoinfected and HIV/HCV co-infected patients in real-life setting 97
Il ruolo del Medico di Medicina Generale nella diagnosi precoce della malattia da HIV. 96
Diagnosi sierologica nelle malattie autoimmuni non organo-specifiche. 95
Direct acting antivirals (DAAs) for the treatment of HCV infection in HIV/HCV coinfected patients: a clinical experience. 94
Hepatitis C virus core antigen: analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay. 93
SARS-CoV-2 mRNA Vaccine Response in People Living with HIV According to CD4 Count and CD4/CD8 Ratio 91
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 91
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50cp/mL. 91
Do we still need CD4 T cell count? 89
Specific changes in the post-translational regulation of nucleolin in lymphocytes from patients infected with human immunodeficiency virus 88
Genotypic Resistance Tests for the Management of Structured Therapeutic Interruptions after Multiple Drug Failure: Prosecution 88
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 87
Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: a multi-cohort study. 87
Humoral and cellular immunity after mRNA COVID-19 vaccine in psoriatic patients on biological or immunosuppressive therapy: a real-life experience 86
Molecular analysis of hepatitis B virus (HBV) in an HIV co-infected patient with reactivation of occult HBV infection following discontinuation of lamivudine-including antiretroviral therapy. 86
Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. 85
Incidence and predictors of single drug discontinuation according to the presence of HCV coinfection in HIV patients from the ICONA Foundation Cohort Study. 84
The effect of dupilumab in an HBV-HIV coinfected atopic patient: a case report 84
Characterisation and outcomes of difficult-to-treat patients in an Italian cohort of PLWHIV starting modern ART regimens. 83
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 83
Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: data from the ICONA foundation study group, years 1997-2013 83
Validation of a self-reported HIV symptoms list: the ISS-HIV symptoms scale. 83
Day-On, Day-Off emtricitabine, tenofovir disoproxil fumarate and efavirenz single tablet regimen (DODO) as maintenance therapy in HIV-infected patients 83
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014. 83
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 83
Diagnostica immunologica. 82
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 82
Specific Anti-Nuclear Antibodies, Clinical Features and Outcome Following Treatment with Nilotinib In Patients with Chronic Graft-Versus-Host Disease. The 44th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Poster Sessions 80
HIV-induced abnormalities in myelopoiesis and their recovery following antiretroviral therapy 79
Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: A cohort study 79
Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort 78
P131 Anlaids community-based HIV screening as a tool to improve HIV diagnosis among asymptomatic individuals 77
Lo studio fenotipico di linfociti e altre cellule mononucleate. 77
OC52 Long-term effectiveness of bictegravir-emtricitabine-tenofovir alafenamide (B/F/TAF) as first-line therapy and as switch strategy in virologically suppressed persons with HIV up to 192-weeks: data from the ICONA-BIC Study 75
Impaired in-vitro growth of megakaryocytic colonies derived from CD34 cells of HIV-1-infected patients with active viral replicatio 75
Polyclonal serum-free light chains elevation in HIV-infected patients. 74
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 74
LA SIEROLOGIA TIPO-SPECIFICA PER HERPES SYMPLEX TIPO 2 NELLA GESTIONE DEI PAZIENTI HIV POSITIVI 74
OC-43 ‘U=U impossibile sbagliare’ awareness campaign: impact assessment among PLWH 72
Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study. 68
Tollerabilità metabolica e durevolezza degli schemi antiretrovirali comprendenti nevirapina. 68
Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV. 67
SC6 Promoting hepatitis and HIV screening in high prevalence populations: the ‘test in the city’ project 65
Switch a raltegravir in un paziente con carcinoma a cellule di Merkel e sarcoma di Kaposi. 65
Soluble CD163 in CMV Infected and Uninfected subjects on Virologically-Suppressive Antiretroviral therapy in the ICONA cohort 64
Il paziente adulto con immunodeficienza. 63
La tollerabilità della terapia antiretrovirale come mezzo per la gestione a lungo termine di pazienti complessi: un caso clinico. 62
La ricerca degli anticorpi anti-nucleo non è sempre di facile interpretazione 61
P128 The role of ancona checkpoint in counseling and facilitating PrEP access through tele-visits 60
Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohort 59
HIV among adolescents and young adults in Italy: focus on epidemiological, viro-immunological and treatment characteristics of 689 18-24 year old subjects enrolled in the ICONA Cohort. 59
Il ruolo del Mmg nella diagnosi precoce della malattia da HIV. 58
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort 53
Infezione da HIV-1. 52
Long-acting injectable antiretrovirals for HIV treatment in the ICONA cohort: physicians’ and nurses’ points of view 51
Trends in Mortality in People With HIV From 1999 through 2020: A Multicohort Collaboration 50
L’immunoricostituzione, un paesaggio dai mutevoli confini 50
Risk of clinical events in virologically suppressed people with HIV switching to a two-drug regimen vs. remaining on a three-drug regimen: a target trial emulation 49
Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort 48
ORCHESTRA Delphi consensus: clinical management of SARS-CoV-2 infection in people with HIV 46
PRIMARY BILIARY CHOLANGITIS CASE- FINDING: AN ITALIAN MULTICENTER OBSERVATIONAL STUDY ON PATIENTS WITH INCIDENTAL FINDING OF ANTI- MITOCHONDRIAL ANTIBODIES. 45
ORCHESTRA Delphi consensus: diagnostic and therapeutic management of post-COVID-19 condition in vulnerable populations 44
La riduzione delle interazioni farmacologiche come mezzo per aumentare l’aderenza alla terapia antiretrovirale e garantirne la durability. 40
Selected comorbidities and the probability of ART switch in PWH with undetectable HIV-RNA: a retrospective analysis in Italy 33
Management of vaccinations in patients with non‐Hodgkin lymphoma 32
Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort 2
Totale 8.332
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.772
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.772
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021617 0 0 0 0 0 44 95 63 126 93 122 74
2021/2022585 37 129 12 34 8 31 30 52 43 48 58 103
2022/20231.153 107 121 75 118 79 230 0 61 277 4 50 31
2023/2024656 105 11 31 85 133 125 18 17 12 13 15 91
2024/20251.541 198 107 56 17 22 60 104 53 418 149 126 231
2025/20262.303 393 387 449 563 467 44 0 0 0 0 0 0
Totale 8.332